Embase
Embase is a biomedical and pharmacological database published by Elsevier. It contains indexed literature that is not readily available in other databases. Embase includes articles from journals that are not indexed by other biomedical sources, particularly those from Europe.
Overview[edit | edit source]
Embase was launched in 1974 by Excerpta Medica, a Dutch publishing company that was later acquired by Elsevier. The database contains over 32 million records from over 8,500 currently indexed journals. Embase's literature is primarily from 1947 to the present, with selected coverage from 1902.
Content[edit | edit source]
Embase covers the fields of drug development, clinical guidelines, treatment evaluation, drug safety, pharmacoeconomics, and pharmacoepidemiology. It also includes the fields of molecular biology, biotechnology, health policy management, public health, occupational health, environmental health, drug dependence and abuse, psychiatry, forensic science, and biomedical engineering.
Features[edit | edit source]
Embase provides access to the most recent and relevant medical literature with a strong focus on evidence-based medicine. It includes unique non-English content and literature from the most important types of evidence, such as systematic reviews, health technology assessments and controlled trials. Embase's comprehensive indexing process uses the Emtree controlled vocabulary, which is updated annually to ensure all records are indexed accurately.
Access[edit | edit source]
Access to Embase is generally provided through institutional subscriptions, such as those held by universities and medical schools. Some public libraries and other non-profit institutions also provide access. Individuals can purchase short-term access to Embase.
See also[edit | edit source]
References[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD